Shaanxi Buchang Pharmaceutical Co., Ltd   Report issue

For profit Phase 2 Phase 4
Founded: Shaanxi China (2009)
Status: No NME R&D (2009)

Organization Overview

First Clinical Trial
2014
NCT02280850
First Marketed Drug
2020
tadalafil (cialis)
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Shaanxi Buchang Pharmaceutical Co., Ltd | Shaanxi Buchang Pharmaceuticals Co., Ltd. | Shandong Buchang Pharmaceutical Co., Ltd. | Shenzhen Yangli Pharmaceutical Technology Co., Ltd | YANGLING BUCHANG

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Angina Pectoris (Phase 4)

Angina, Stable (Phase 4)

Blind Loop Syndrome (Phase 2)

Coronary Artery Disease (Phase 2)

Disease (Phase 4)

Parasomnias (Phase 4)

Peripheral Nervous System Diseases (Phase 2)

Sleep Wake Disorders (Phase 4)

Vaginitis (Phase 4)

Vaginosis, Bacterial (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 6
  • # of Trial APIs: 8